You are here: Home:Audio Program Guide: BCU 2 | 2005   Go to interview with Jenny C Chang, MD Go to interview with I Craig Henderson, MD Go to interview with Professor Sir Richard Peto Go to interview with Maura N Dickler, MD

To listen to individual tracks now, click the icon. To download tracks to a CD, right-click the icon for your preferred file type. Files are provided in WMA for users with Windows Media Player or MP3 for users with other audio players.

Jenny C Chang, MD Associate Professor Breast Center at Baylor College of Medicine Houston, Texas Click here to download the entire interview WMA MP3
Track 1	Introduction by Neil Love, MD
Track 2	Gene expression profiling to find predictors of response to neoadjuvant docetaxel
Track 3	Differences in predictors of response to docetaxel and AC chemotherapy
Track 4	Developing clinical assays to test for predictors of response to chemotherapeutic agents
Track 5	Induction of apoptosis with neoadjuvant trastuzumab
Track 6	Benefit of testing biologic agents in the neoadjuvant setting
Track 7	Predictors of response to tyrosine kinase inhibitors versus trastuzumab
Track 8	Need for larger trials to confirm MD Anderson neoadjuvant trastuzumab results
Track 9	Biologic rationale for the benefit of pan-HER2 inhibition
Track 10	New clinical research strategies with biologic therapies
Track 11	Cardiac toxicity associated with trastuzumab
Track 12	Nonprotocol use of neoadjuvant and adjuvant trastuzumab
Track 13	Management of HER2-positive metastatic disease
Track 14	Role of fulvestrant in clinical practice
I Craig Henderson, MD Adjunct Professor of Medicine University of California, San Francisco San Francisco, California Click here to download the entire interview
Track 1	Introduction by Dr Love
Track 2	Heterogeneity of breast cancer
Track 3	Selection of optimal adjuvant hormonal therapy
Track 4	Difficulty showing survival advantage in adjuvant trials of older patients with low-risk disease
Track 5	Carryover effect with adjuvant hormonal therapy
Track 6	Selection of an aromatase inhibitor versus tamoxifen based on toxicity profiles
Track 7	Time course for switching from tamoxifen to an aromatase inhibitor
Track 8	Limitations of current methods to classify breast cancer
Track 9	Impact of false-negative research findings on drug development
Track 10	New research strategies to identify effective therapies and combinations
Track 11	Ongoing development of novel AKT inhibitor KRX-0401
Track 12	Cancer as a chronic disease
Professor Sir Richard Peto Clinical Trial Service Unit (CTSU) University of Oxford Oxford, United Kingdom Click here to download the entire interview
Track 1	Introduction by Dr Love
Track 2	Impact of all-cause mortality on clinical trial results
Track 3	Carryover effect of therapies for the treatment of breast cancer
Track 4	Rationale for reductions in breast cancer mortality over the past 10 years
Track 5	Impact of screening mammography on decreases in breast cancer mortality
Track 6	Extended adjuvant tamoxifen: ATLAS and aTTom trials
Track 7	Impact of CAN-NCIC-MA17 results on the ongoing ATLAS trial
Track 8	False-negative ER assays
Track 9	Relationship between ER status of primary and contralateral breast cancers
Track 10	Role of ovarian ablation in combination with other effective therapies
Track 11	Need for clinical trials of adjuvant chemotherapy in elderly women
Track 12	Impact of local tumor control on breast cancer mortality
Track 13	Cardiac effects of postmastectomy radiotherapy

Maura N Dickler, MD Assistant Attending Physician Breast Cancer Medicine Service Memorial Sloan-Kettering Cancer Center New York, New York Click here to download the entire interview
Track 1	Introduction by Dr Love
Track 2	Phase II trial of bevacizumab and erlotinib for patients with metastatic disease
Track 3	Potential value of measuring circulating tumor cells
Track 4	Response rates of single-agent bevacizumab and tyrosine kinase inhibitors in breast cancer
Track 5	Management of patients with HER2-positive metastatic disease
Track 6	Benefit of avoiding premedication with nanoparticle paclitaxel
Track 7	Potential role of nanoparticle paclitaxel in clinical practice
Track 8	Selection of combination chemotherapy in the metastatic setting
Track 9	Benefits of treating patients with capecitabine
Track 10	Rationale for up-front use of adjuvant anastrozole
Track 11	Time course for initiating an aromatase inhibitor after five years of tamoxifen
Track 12	Nonprotocol use of neoadjuvant and adjuvant trastuzumab
Track 13	Patient preferences for oral versus parenteral endocrine therapy